Influence of mouse genotype on passive systemic anaphylaxis by immune complexes by Portoles, A. (Antonio) et al.
Vol. 54, No. 3INFECTION AND IMMUNITY, Dec. 1986, p. 882-885
0019-9567/86/120882-04$02.00/0
Copyright © 1986, American Society for Microbiology
Influence of Mouse Genotype on Passive Systemic Anaphylaxis by
Immune Complexes
ANTONIO PORTOLES,1* JOSE M. ROJO,'t AND RAMON DiAZ2
Instituto de Inmunologia y Biologia Microbiana, Velazquez 144, 28006, Madrid,' and Departamento de Microbiologia,
Facultad de Medicina, Universidad de Navarra, Pamplona,2 Spain
Received 13 June 1986/Accepted 4 September 1986
The influence of mouse genotype on passive systemic anaphylaxis (PSA) by immune complexes was studied.
PSA was induced by using Brucella abortus endotoxin as the antigen and rabbit anti-Brucella endotoxin
antisera. Experiments using syngeneic mice as weli as mice congenic for H-2 showed that the H-2 haplotype
influenced the sensitivity of mice to PSA. Among the H-2 haplotypes studied, H-2b was the most sensitive,
followed by H-2k and H-2d. Experiments using passive transfer of serum as well as the complement inhibitors
suramin and flufenamic acid indicated that variations in complement levels under control of H-2 may be
responsible for the effects described. Cyproheptadine, a blocker of serotonin and histamine receptors, and
imidazol-a-ketoglutarate, an inhibitor of thromboxane synthesis, inhibited PSA, indicating that platelet
aggregation, possibly mediated by activated components of the complement cascade, is an important feature in
the development of PSA reactions in this system. Differences between strains for protection by cyproheptadine
and for the effect of complement inhibitors indicated a role of early components of the classical pathway in this
model.
The process of active immune-complex deposition in
vessels and tissues appears as a pathogenic mechanism of
neuritis, vasculitis, and glomerulonephritis, with a possible
anaphylactic origin (5, 12, 18, 26). The size of immune
complexes is a critical factor in determining their clearance
from the circulatory system (24). It has been proposed that
the size of immune complexes mainly depends on the
antigen-antibody ratio, the number of antigenic determi-
nants, and the affinity between antigen and antibody (7, 12,
26). Some relationships between the size of the immune
complexes and the heterogeneity of antibodies have also
been described (15), and we have used passive systemic
anaphylaxis (PSA) by immune complexes as a model to
study atherogenic processes in mice through the vascular
deposition of the complexes (21).
In this work, we report the influence of the genetic
background of mice on their responses to PSA produced by
immune complexes. Clear differences between mice bearing
the H_2b, H-2d, and H-2k haplotypes were found. In addition,
cyproheptadine chlorohydrate (CY), a blocker of serotonin
and histamine receptors (3), ticlopidine (TC), an inhibitor of
platelet aggregation (17, 25), and imidazol-a-ketoglutarate
(a-IK), which inhibits thromboxane synthesis (11), were
used to ascertain possible differences in the pathogenic
mechanisms of PSA among strains.
MATERIALS AND METHODS
Antigen. The f5 endotoxic fraction (f5) obtained from
Brucella abortus 2308 by the Westphal method (2) was used
as the antigen. Cultures grown for 48 h at 37°C in a rotary
shaker on Trypticase soy broth (BBL Microbiology Sys-
tems, Cockeysville, Md.) were used as the cell source for
obtaining endotoxin.
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Antiserum. Rabbit anti-f5 endotoxic fraction antibody was
prepared essentially as previously described (21). High-
titered rabbit antisera were obtained 1 month after injecting
intravenously (i.v.) 2 x 109 bacteria in 0.5 ml of phosphate-
buffered saline.
Drugs. CY (Merck Sharp & Dohme, Madrid, Spain), TC
(Arcor, Toulouse, France), and a-IK (UCB Laboratorios,
Barcelona, Spain) were assayed as protective drugs in PSA
responses. Suramin (Germanine Bayer, Leverkusen, Fed-
eral Republic ofGermany) and flufenamic acid (Laboratorios
Hubbert S.A., Barcelona, Spain) were used as pharmaco-
logical inhibitors of complement-mediated effects. Ovalbu-
min (Sigma Chemical Co., St. Louis, Mo.) was used in rabbit
immunizations to obtain antisera for ovalbumin-antiovalbu-
min complexes. Human immunoglobulin (Cohn fraction II
and III; Sigma) was used to prepare heat-aggregated globu-
lin.
Animals. All experiments were performed with 8- to
10-week-old male mice from the congenic strains BALB/c,
BALB.B, and BALB.K or the strains C3H, C57BL/6, and
DBA/2. All mouse strains were from the Animal Housing
Department of our center and were initially obtained from
Olac Ltd. Animals were housed in plastic cages with water
and food ad libitum with a 12:12 day-to-night photoperiod.
PSA response. The procedure used to elicit PSA by im-
mune complexes in mice has been described before (20).
Briefly, mice were sensitized by an i.v. injection of 0.2 ml of
a rabbit antiserum raised against endotoxin (f5) from B.
abortus 2308 (2). After 3 h, the sensitized mice received i.v.
injections of 0.75 mg (two times the 50% lethal dose) of the
same endotoxin in 0.2 ml of saline. Lethal anaphylactic
shocks were recorded at different times after the second
injection (see below). Under these experimental conditions,
animals affected by anaphylactic reaction died sooner (be-
fore 24 h) and showed classic specific symptoms; after 36 h,
we considered they had overcome the anaphylactic phenom-
enon and were variably protected from the toxicity of f5 by
the anti-fS antiserum. As previously reported (8), the dif-
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FIG. 1. MTD in mice after induction of PSA by immune com-
plexes. Groups of 10 to 12 mice of the indicated strains were
sensitized by i.v. administration of 0.2 ml of rabbit antiserum against
B. abortus 2308 endotoxin. PSA was induced 3 h later by i.v.
injection of 0.75 mg of the antigen (B. abortus 2308 endotoxin [fS])
in 0.2 ml of saline. Abscissa, ratio of dead to surviving mice;
ordinate, log of MDT time after antigen administration. Intersec-
tions with ordinate indicate logl0 hour of populational MTD calcu-
lated by nomograms (20) from the origin (death of the first mouse)
and for the time of death of all other mice. MTD + the standard
deviation in hours was calculated as the antilogarithm from these
values and is represented between brackets.
ferent effects of endotoxin are perfectly distinguishable in
the mouse model proposed.
To investigate the possible influence of complement in the
PSA response, pharmacological inhibition of complement
activity by suramin (10) and flufenamic acid (P. F. Kohler
and J. S. Martinez, Fed. Proc., p. 472, 1971) was studied.
For passive transfer of serum, either 0.25 ml of normal
mouse serum or the same volume of complement-depleted
serum was administered i.v. Complement-depleted serum
samples were prepared as described previously (16); briefly,
antigen-antibody complexes were obtained with ovalbumin
and a rabbit antiovalbumin serum mixed at the equivalence
point and incubated at 4°C for 24 h. The immune complexes
were washed three times with cold saline, and equal samples
of these antigen-antibody complexes were mixed with 2 ml
of mouse serum. The sera obtained were used after 24-h
incubations at 4°C. In some cases, drugs (CY, TC, and a-IK)
were perorally administered as a suspension in 0.5% car-
boxymethyl cellulose 2 h before serum sensitization and
their effects were compared to groups of mice receiving
carboxymethyl cellulose only.
Data analysis. A computer-assisted BASIC program was
used for analysis and comparison of mean time of death
(MTD). The relationship between the survival index and
time was fitted by means of a regression line. The signifi-
cance of differences between data was calculated by using a
Student's t test. Differences were considered significant
when P < 0.02.
RESULTS AND DISCUSSION
In previous studies with several strains of mice, we
observed marked differences in PSA responses among
strains (data not shown). Consequently, we performed ex-
periments in which groups of 10 to 12 mice from inbred
strains were tested for their sensitivity to PSA. The results
were recorded as MTD calculated from nomograms (20)
(Fig. 1). It was clear from the data obtained that C3H,
BALB.K, and especially C57BL/6 and BALB.B mice had
MTDs shorter than those of BALB/c and DBA/2 mice. The
susceptibilities to PSA of the different strains of mice in
relation to some of their genetic traits are shown in Table 1.
The data show that sensitivity to PSA by immune complexes
could be correlated with the H-2 haplotype of the mice, since
strains BALB.B and C57BL/6 (H-2b) were very sensitive to
PSA; BALB.K and C3H were slightly less sensitive to
anaphylaxis, and BALB/c and DBA/2 (H-2d) were markedly
resistant. The hypothesis that there is a relationship between
the H-2 haplotype and sensitivity to PSA is supported by the
fact that BALB.B and BALB.K are strains selected for
differences in H-2 haplotype in a BALB/c background.
One possible mechanism by which the H-2 haplotype
could influence PSA is through complement, whose func-
tional levels in relation with H-2 have been studied (6),
especially for the early components of the complement
cascade (13). It has been reported (14) that the formation of
immune complexes causes platelet aggregation and hista-
mine release by complement-mediated mechanisms. In ad-
dition, there are indications that stimulation of phagocytes
through C3b receptors induces the release of platelet-
activating factor (22). In mice, the Ss locus of H-2 deter-
mines high or low levels of the Ss protein, which was later
identified as C4 (23). Our data show that PSA-susceptible
strains can be either SSh or Ss' (Table 1). However, Demant
et al. (6) reported that Ssh mice have high levels of functional
complement only when they express a certain Slp allotype
(SIp') but not when they express other allotypes (Slp°) (6)
(Table 1). Surprisingly, we found that all the PSA-sus-
ceptible strains had low levels of complement as defined by
Demant et al. (6) and PSA-resistant strains had high levels of
complement. Although these data indicate that there is no
TABLE 1. Susceptibility to PSA of several strains of inbred mice
Mouse strain H-2 haplotype Ss-Slp region Complement level' MTD (h + SD)b Susceptibility to PSA
BALB.B b Ssh-SIpo Low 1.90 ± 0.05 High
C57BL/6 b Ssh-SIpo Low 1.84 ± 0.06 High
BALB.K k SsL'Slp° Low 3.12 ± 0.15 High
C3H k Ss'-Slp° Low 2.39 ± 0.11 High
BALB/c d SSh_Slpa High 53.72 ± 0.31 Low
DBA/2 d SSh_Slpa High 39.28 ± 0.22 Low
a As described by Ddmant et al. (6).
b Evaluated by nomograms (20) by using a computer-assisted program.
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FIG. 2. Variations in the MTD after serum transfer assays (A)
and after treatments with complement-inhibitory drugs (B). (A)
MTD of normal BALB/c mice (CA) or BALB/c mice injected i.v.
with 0.25 ml of normal BALB.B serum (nD) given 30 min before
sensitization with B. abortus endotoxin are depicted. Another group
of BALB/c mice received BALB.B serum depleted of complement
(D) as described in Materials and Methods. (B) The effect of suramin
(S) (i.v. dose, 10 mg/kg, 2 h before sensitization) or flufenaniic acid
(F) (oral dose, 200 mg/kg, 2 h before sensitization) on the MTD of
BALB.B mice (CB). The statistical significance of the difference
from the control is given in brackets.
correlation between PSA sensitivity and high complement
levels, results from additional experiments suggest an impor-
tant role of complement in PSA. To study this, two experi-
mental approaches were followed: (i) passive transfer of
normal mouse serum from a high-susceptibility strain to a
low-susceptibility strain before or after complement deple-
tion by antigen-antibody complexes (16) and (ii) treatment of
mice with complement-inhibitory drugs to depress comple-
ment-mediated effects. Results of these experiments are
presented in Fig. 2, in which the variations ofPSA responses
in the resistant BALB/c mice subsequent to serum transfer
from sensitive strains are indicated (Fig. 2A). As can be
seen, high susceptibility to PSA in H-2d mice could be
obtained by passive transfer of normal serum from the
susceptible H-2b mice. In these cases, the MTD of BALB/c
mice was more than four times lower, but this effect was
drastically decreased when BALB.B serum samples were
depleted of complement by treatments with ovalbumin-
antiovalbumin immune complexes. Similar results were ob-
tained by using heat-aggregated (63°C, 20 min) human im-
munoglobulin to deplete complement activity (data not
shown).
On the other hand, the high susceptibility of BALB.B
mice to PSA diminished when animals were treated with the
complement-inhibiting drugs suramin and flufenamic acid;
MTD was augmented more than six times by treatment with
suramin (10 mg/kg) and more than four times by flufenamic
acid (4 mg/kg). This inhibitory effect indicates a role for
classical pathway activation in the PSA response and may be
similar to inhibition of the Arthus reaction in rabbits treated
with suramin or flufenamate (for a review, see reference 1).
The mechanism by which H-2 influences complement
levels is not clear, although there are some indications that
H-2 may control the levels of other components of the
complement system that are different from C4. Ferreira and
Nussenzweig (9) reported that AKR/J mice (H-2) have
serum C3 levels higher than DBA/2J mice (H-2d). Studies
with hybrids and backcrosses to the parental strains showed
that the levels of C3 were controlled by a gene(s) linked to
the H-2 complex. Higher levels of C3 in H-2k than in H_2d
mice fit with the high or low sensitivity to PSA of mice from
these haplotyes (Table 1), but the complexity of the system
requires a careful analysis at the genetic level.
Another aspect studied was the implication of platelet
aggregation in our model of PSA. As mentioned above, there
is evidence for complement-mediated mechanisms of plate-
let activation (14, 22). Consequently, several treatments with
drugs that prevent platelet aggregation were established in
order to examine the mechanism of PSA. Variations in PSA
by immune complexes after treatment with CY, TC, and
a-IK are presented in Table 2 for each of the strains of mice.
CY, which blocks serotonin and histamine receptors (3), was
protective for PSA, especially in mice of the H-2k haplotype,
pointing to a role of platelet aggregation in PSA. Another
drug assayed was a-IK, an inhibitor of thromboxane synthe-
sis (11), which protected the animals from PSA to some
degree. The third drug under study was TC, which alters
arachidonic acid metabolism in platelets, augmenting pros-
taglandin E2 (PGE2) and PGD2 synthesis and lowering
thromboxane synthesis without diminishing endoperoxide
production (17). Thus, TC could favor PGI2 synthesis by the
vascular endothelium and, consequently, inhibit platelet
aggregation. TC, however, did not show any protective
effect under the experimental conditions used (Table 2).
Taken together, these results suggest that PSA is mediated
by the aggregation of platelets and release of vasoactive
amines. In addition, we observed in a previous study (21)
that etofibrate, an antiatherogenic drug which inhibits plate-
let aggregation (19), can also inhibit PSA in mice. It is
interesting that there are some differences among strains in
protection by CY and a-IK (Table 2). BALB/c and DBA/2
mice were comparatively less protected by these treatments
than were the other strains, indicating that several factors
could influence the outcome of PSA responses. In addition,
a differential behavior in CY-treated H-2k and H-2b mice was
TABLE 2. Variations in survival of different strains of mice after single-dose drug treatments
PSA responses (MTD in h + SD) with and without":Mouse strain
Without drug CY (0.2 mg/kg) TC (7.5 mg/kg) a-IK (25 mg/kg)
BALB.B 1.92 ± 0.05 5.85 ± 0.19 2.93 ± 0.06 4.86 ± 0.17
C57BL/6 1.81 ± 0.04 5.00 ± 0.11 3.44 ± 0.11 3.78 ± 0.08
BALB.K 3.09 ± 0.12 26.95 ± 0.13 2.67 ± 0.03 7.82 ± 0.15
C3H 2.26 ± 0.09 11.89 ± 0.06 2.20 ± 0.01 6.52 ± 0.09
BALB/c 54.32 ± 0.33 60.42 ± 0.15 29.21 ± 0.09 74.99 ± 0.52
DBA/2 39.35 ± 0.25 57.85 ± 0.23 26.77 ± 0.12 43.31 ± 0.38
a Drugs were orally administered as suspensions in 0.5% carboxymethyl cellulose 2 h before serum sensitization.
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observed, since H-2k animals were more effectively pro-
tected than were H-2b mice by CY. One of the factors
influencing protection by CY could well be the levels of the
early components of the classical activation pathway, be-
cause, according to Goldman and Goldman (13), H-2b mice
of the have higher levels of Cl, C4, and C2 than H-2k mice.
Thus, the protection by CY is more effective when the levels
of these components are low, stressing the importance of the
classical pathway in the outcome of the PSA response in our
model.
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